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thus force tumor cells with supernumerary centrosomes to
undergo multipolar mitoses and consequently apoptosis.
Results: This approach led to the identification of several sub-
stances which are currently characterized in more detail. One of
these substances is the well-known antifungal drug griseofulvin,
which, in addition to its inhibition of centrosomal clustering
described here, has recently been shown to suppress microtubule
dynamic instability.
Conclusion: Taken together, this screening may help identify
new potential anti-cancer drugs.
doi:10.1016/j.ejcsup.2006.04.106
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Background: Protection of normal tissue against radiation-
induced damage would increase the therapeutic ratio of
radiotherapy. A promising strategy for this approach is gene
therapy-mediated overexpression of copper–zinc (CuZnSOD)
and manganese superoxide-dismutase (MnSOD). Recombinant
adeno-associated virus 2 (rAAV2) are attractive vectors owing
to their ability to infect non-dividing cells and a very low risk
of insertional mutagenesis. The purpose was to test the radio-
modulating effects of SOD on human primary lung fibroblasts
(HPLF).
Methods: Low passage HPLF (MRC5) cells were transduced with
the rAAV2-SOD vectors, harvested on day 3, irradiated (1–8 Gy)
and analysed using FACS, Western blot, SOD-activity and colony
formation assays.
Results: High transduction rates were obtained with >80% of the
HPLF cells expressing the respective SOD. Compared to transduc-
tion controls, CuZnSOD did not exhibit any radioprotective
effects, whereas for MnSOD-transduced HPLF an increase of
approximately 30% in the survival of colony-forming cells was
observed (1–4 Gy).
Conclusion: An increase in clonogenic survival (1.3-fold) of HPLF
cells after transfer of MnSOD and subsequent irradiation was
shown. Earlier, we have shown lack of protection in tumour cells
(HeLa), thus supporting that MnSOD may increase the therapeutic
ratio. rAAV2 vectors are promising tools for the delivery of radio-
protective genes in normal tissue such as the lung for pulmonary
or intestine cells for prostate irradiation.
doi:10.1016/j.ejcsup.2006.04.107
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Background: The normal development and functioning of the
prostate gland, as well as its benign and neoplastic growth is
dependent of androgen. Previous studies with Gonadotrophin
Realeasing Hormone (GnRH/LHRH) vaccines, have shown the use-
fulness of immunization against this hormone in prostate and
breast cancer.
Methods: In this work we have designed a vaccine candidate
called GnRHm1-TT based on a completely synthetic immunogen.
The peptide was formulated as a white semiviscous water in oil
preparation and injected to animals.
Results: In healthy animals, this vaccine candidate showed to
be very immunogenic, resulting in high anti-GnRH antibodies
titers, testosterone reduction and significant decrease of the
prostate and testicle weight. In tumor implanted rats the
vaccine candidate had demonstrated to produce significant
tumor growth inhibition of Dunning R3327-H androgen respon-
sive prostate tumor in rats P = 0.025 and survival increase,
P = 0.001.
Conclusion: GnRHm1-TT have demonstrated to be highly immu-
nogenic and safe, causing prostate and testicle atrophy and sig-
nificantly tumor growth inhibition. These results make our
vaccine candidate useful as an effective androgen deprivation
therapy, and possible application to prostate cancer and other
hormone-dependent malignancies therapy.
doi:10.1016/j.ejcsup.2006.04.108
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Background: Beside their use as anti resorptive drug, bisphos-
phonates are well known to stimulate cd T cells and to have direct
effects on tumor growth.
Methods: We determined the direct cytotoxic effect of pamidro-
nate and zoledronic acid, the induction of apoptosis and their
anti-metastatic potential. Next, we analyzed how bisphospho-
nates act on cd T cells propagated with our recently published
protocol. The susceptibility of pancreatic carcinoma cells pre-
treated with bisphosphonates against cd T cells was tested in
cytotoxicity assays and the subgroup involved in killing was
investigated.
E J C S U P P L E M E N T S 4 ( 2 0 0 6 ) 2 7 –5 3 45Results: Zoledronic acid but not pamidronate has a cytotoxic
potential even at pharmacological dosage. Zoledronic acid does
not only induce apoptosis by inhibiting the Ras-pathway but
has also an anti-metastatic effect. Freshly prepared cd T cells con-
sisting mainly of Vd2 cells showed increased cytotoxicity against
bisphosphonate-treated pancreatic carcinoma cells. cd T cells
could be expanded fourfold by use of anti-CD3 and IL-2. However,
activated. cd T cells do not respond to bisphosphonates and kill
mainly in a Vd1 dependent manner.
Results: Our results demonstrate that zoledronic acid has a
direct apoptotic effect on pancreatic carcinoma cells and has
anti-metastatic properties. Tumor cells treated with zoledronic
acid are more susceptible against Vc9 Vd2 T cells, the most abun-
dant population of cd T cells in the peripheral blood. Treatment
with zoledronic acid for patients with pancreatic carcinoma
might be an option.
doi:10.1016/j.ejcsup.2006.04.109
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Background: Tetraspanins are involved in cell activation, prolif-
eration, adhesion, motility and cell fusion. Some members
including D6.1A are known to promote metastasis formation.
Overexpression of the tetraspanin D6.1A on a rat pancreatic ade-
nocarcinoma line BSp73AS (BSp73AS-D6.1A) is associated with
the formation of haemorrhagic ascites and can induce dissemi-
nated intravascular coagulation.
Methods: Angiogenesis was analysed by intravital microscopy
of the rat mesentery 6 days after intraperitoneal tumor cell
application and after co-culture of the mesentery with tumor
cells, supernatant of the tumor cells and tumor cell derived
exosomes.
Results: D6.1A expressing tumor cells induced strong angio-
genesis with vessels covering roughly 25% of the tumor area
as compared to 5% in BSp73AS tumors. Also mesenteric cells
displayed strikingly increased branching in co-cultures with
BSp73AS-D6.1A cells, supernatant thereof or tumor cell derived
exosomes. A D6.1A-specific antibody completely inhibited
BSp73AS-D6.1A-, but also BSp73AS-induced angiogenesis
in vivo and in vitro. This finding suggested the existence of
an additional antibody target that has been identified as prolif-
erating endothelial cells, which strongly upregulate D6.1A
expression.
Conclusion: Tumor derived D6.1A is a strong angiogenesis indu-
cer, that indicates for an angiogenic loop due to the striking
upregulation of D6.1A on endothelial cells. Because of the latter,
the antibody-mediated suppression of the angiogenesis likely
offers a very effective and selective drug.
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Background: Histone deacetylase inhibitors (HDACi) are novel
anti-tumor compounds currently being tested in clinical trials.
Our laboratory has previously shown that in cultured cells
HDACi-induced cell death was mediated by mitochrondrial dam-
age, cytochrome C release and Bid cleavage. However, it is pres-
ently unclear which apoptotic pathways are utilized by HDACi
in vivo, i.e. in a therapeutic setting. Moreover, it is poorly under-
stood how molecular events during anti-cancer drug-mediated
apoptosis relate to therapeutic outcome.
Methods: We have employed the murine El-myc B-cell lym-
phoma model to directly compare HDACi-induced cell death
in vitro with therapeutic efficacy in vivo. Our system comprises
lymphomas with defined genetic alterations in the apoptotic
machinery and the tumors can either be grown and treated
in culture or transplated into immunocompetent animals for
therapy studies. Using this system, we have identified key
apoptotic molecules that not only control sensitivity of cultured
lymphoma cells to HDACi, but also determine therapeutic
outcome.
Results: Overexpression of Bcl2, previously linked to treatment
failure in human cancers, conferred complete chemoresistance
in vitro and in vivo. Strikingly, the HDACi SAHA eradicated El-
myc lymphomas in a p53-independent manner, resulting in pro-
longed survival after SAHA treatment of p53/ lymphomas.
Constraining the cellular apoptotic program by genetic targeting
of Apaf-1, Caspase-9 and Bid impinged on in vitro sensitivity
and we are currently investigating whether this is associated with
tumor relapse and chemoresistance while animals are under
therapy.
doi:10.1016/j.ejcsup.2006.04.111
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Introduction: The X-ray cross-complementing gene XRCC1 and
the excision repair cross-complementing group 2 gene ERCC2
(XPD) are involved in the repair of DNA modifications resulting
from DNA-damaging agents used in cancer therapy. Functional
